Home
LXRX
LXRX News

Latest Lexicon Pharmaceuticals Inc. (LXRX) News on May 11, 2025

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

GlobeNewswire

5 days ago

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

GlobeNewswire

5 days ago

Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?

Zacks

a month ago

LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire

a month ago

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

MT Newswires

a month ago

Social Buzz: Wallstreetbets Stocks Mixed Premarket Tuesday; Tesla to Advance, Lexicon Pharmaceuticals to Decline

Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1

Investor's Business Daily

a month ago

Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1

MT Newswires

a month ago

Top Midday Gainers

Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug

Pharmaceutical Technology

a month ago

Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug

MT Newswires

a month ago

Sector Update: Health Care Stocks Steady Premarket Friday

MT Newswires

a month ago

Lexicon Pharmaceuticals Enters License Agreement With Novo Nordisk for Obesity Drug; Shares Jump

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

GlobeNewswire

a month ago

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025

GlobeNewswire

2 months ago

Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025

Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ...

GuruFocus.com

2 months ago

Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ...

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates

Zacks

2 months ago

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates

Associated Press Finance

2 months ago

Lexicon: Q4 Earnings Snapshot

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

GlobeNewswire

2 months ago

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

MT Newswires

2 months ago

Leerink Partners Downgrades Lexicon Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $1 From $2

Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

GlobeNewswire

2 months ago

Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

MT Newswires

2 months ago

Lexicon Says Pilavapadin Showed 'Meaningful' Pain Reduction But Results Miss Primary Endpoint

Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

GlobeNewswire

2 months ago

Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

GlobeNewswire

2 months ago

Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)

GlobeNewswire

3 months ago

Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)

Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain

GlobeNewswire

4 months ago

Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain

Here’s Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10

Insider Monkey

4 months ago

Here’s Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10

MT Newswires

4 months ago

Lexicon Pharmaceuticals Names Scott Coiante Finance Chief

Lexicon Appoints Scott Coiante as Chief Financial Officer

GlobeNewswire

4 months ago

Lexicon Appoints Scott Coiante as Chief Financial Officer

Private equity firms account for 47% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) ownership, while institutions account for 33%

Simply Wall St.

4 months ago

Private equity firms account for 47% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) ownership, while institutions account for 33%

MT Newswires

5 months ago

Lexicon Fails to Secure FDA Approval for Zynquista -- Shares Fall After Hours

Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)

GlobeNewswire

5 months ago

Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)

Lexicon completes subject enrolment for DPNP trial of LX9211

Clinical Trials Arena

5 months ago

Lexicon completes subject enrolment for DPNP trial of LX9211

Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

GlobeNewswire

6 months ago

Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Lexicon Pharmaceuticals to Participate in December Investor Conferences

GlobeNewswire

6 months ago

Lexicon Pharmaceuticals to Participate in December Investor Conferences

MT Newswires

6 months ago

Sector Update: Health Care

MT Newswires

6 months ago

HC Wainwright Cuts Price Target on Lexicon Pharmaceuticals to $4 From $6, Maintains Buy Rating

MT Newswires

6 months ago

Lexicon Pharmaceuticals to Cut 60% of Workforce

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA

GlobeNewswire

6 months ago

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA

Lexicon to disband sales team, lay off 60% of staff

BioPharma Dive

6 months ago

Lexicon to disband sales team, lay off 60% of staff

Lexicon Appoints Ivan H. Cheung to Board of Directors

GlobeNewswire

6 months ago

Lexicon Appoints Ivan H. Cheung to Board of Directors

Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week

Simply Wall St.

6 months ago

Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week

Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago

GlobeNewswire

6 months ago

Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...

GuruFocus.com

6 months ago

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...

Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates

Zacks

6 months ago

Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates

Associated Press Finance

6 months ago

Lexicon: Q3 Earnings Snapshot

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

6 months ago

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For

GuruFocus.com

6 months ago

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For

Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference

GlobeNewswire

6 months ago

Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference

A diabetes drug, twice rejected, stumbles again — but its developer persists

Pharma Voice

6 months ago

A diabetes drug, twice rejected, stumbles again — but its developer persists

Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease

GlobeNewswire

6 months ago

Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024

GlobeNewswire

6 months ago

Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024

Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss

GlobeNewswire

6 months ago

Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss

MT Newswires

6 months ago

Sector Update: Health Care Stocks Rise Late Afternoon

MT Newswires

6 months ago

Top Midday Decliners

MT Newswires

6 months ago

Lexicon Pharmaceuticals Says FDA Panel Opposes Zynquista for Type 1 Diabetes and Kidney Disease

MT Newswires

6 months ago

Top Premarket Decliners

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

GlobeNewswire

6 months ago

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

FDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting

TipRanks

6 months ago

FDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting

New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024

GlobeNewswire

7 months ago

New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024

Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

GlobeNewswire

7 months ago

Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europe

BioPharma Dive

7 months ago

Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europe

Lexicon partners Viatris for global expansion of sotagliflozin

Pharmaceutical Technology

7 months ago

Lexicon partners Viatris for global expansion of sotagliflozin

MT Newswires

7 months ago

Lexicon Pharmaceuticals to Get $25 Million From Viatris in Global Sotagliflozin Licensing Deal

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe

GlobeNewswire

7 months ago

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe

PR Newswire

7 months ago

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe

Lexicon Pharmaceuticals Inc (LXRX) Q2 2024 Earnings Call Highlights: Strategic Advancements ...

GuruFocus.com

7 months ago

Lexicon Pharmaceuticals Inc (LXRX) Q2 2024 Earnings Call Highlights: Strategic Advancements ...

Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

GlobeNewswire

7 months ago

Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

MT Newswires

8 months ago

Lexicon Pharmaceuticals COO Jeff Wade Steps Down

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer

GlobeNewswire

8 months ago

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer

New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes

GlobeNewswire

8 months ago

New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes

Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences

GlobeNewswire

8 months ago

Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences

New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA® (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration

GlobeNewswire

8 months ago

New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA® (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration

Lexicon Pharmaceuticals, Inc. (LXRX): The Best Multibagger Penny Stock of 2025?

Insider Monkey

8 months ago

Lexicon Pharmaceuticals, Inc. (LXRX): The Best Multibagger Penny Stock of 2025?

Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More

Zacks

8 months ago

Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More

Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista

Zacks

9 months ago

Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista

Lexicon to face FDA AdComm for Zynquista approval in diabetes and CKD

Pharmaceutical Technology

9 months ago

Lexicon to face FDA AdComm for Zynquista approval in diabetes and CKD

MT Newswires

9 months ago

Lexicon Pharmaceuticals Says FDA to Hold Meeting in October to Review Zynquista for Type 1 Diabetes, CKD

Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista

GlobeNewswire

9 months ago

Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista

Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up

Zacks

9 months ago

Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up

MT Newswires

9 months ago

Correction: Lexicon Pharmaceuticals Plans Job Cuts as Part of Cost-Cutting Measures

MT Newswires

9 months ago

Lexicon Pharmaceuticals Plans Job Cuts as Part of Cost-Cutting Measures

Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio

GlobeNewswire

9 months ago

Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio

Lilly opens R&D hub; Ovid and Lexicon lay off staff

BioPharma Dive

9 months ago

Lilly opens R&D hub; Ovid and Lexicon lay off staff

Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists

GlobeNewswire

9 months ago

Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists

Lexicon Pharmaceuticals Insider Buyers Pleased With US$724k Return On Investment

Simply Wall St.

9 months ago

Lexicon Pharmaceuticals Insider Buyers Pleased With US$724k Return On Investment

MT Newswires

9 months ago

Lexicon Pharmaceuticals Files $200 Million Mixed Shelf

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates

Zacks

9 months ago

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates

Associated Press Finance

9 months ago

Lexicon: Q2 Earnings Snapshot

Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

9 months ago

Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024

GlobeNewswire

10 months ago

Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024

Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates

Zacks

10 months ago

Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates

FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug

Zacks

10 months ago

FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug

MT Newswires

10 months ago

Update: FDA Sets Target Action Date for Lexicon Pharmaceuticals' NDA Resubmission for Sotagliflozin

MT Newswires

10 months ago

FDA Sets PDUFA Goal Date for Lexicon Pharmaceuticals' NDA Resubmission for Sotagliflozin

Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission

GlobeNewswire

10 months ago

Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission

New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure

GlobeNewswire

10 months ago

New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure

Private equity firms account for 48% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) ownership, while individual investors account for 33%

Simply Wall St.

10 months ago

Private equity firms account for 48% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) ownership, while individual investors account for 33%

Strength Seen in IDEAYA Biosciences (IDYA): Can Its 15.3% Jump Turn into More Strength?

Zacks

10 months ago

Strength Seen in IDEAYA Biosciences (IDYA): Can Its 15.3% Jump Turn into More Strength?

MT Newswires

10 months ago

Lexicon Pharmaceuticals Names Mike Exton CEO, Jeff Wade Operating Chief

Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director

GlobeNewswire

10 months ago

Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director

MT Newswires

a year ago

Sector Update: Health Care Stocks Gain in Late Afternoon

MT Newswires

a year ago

Lexicon Pharmaceuticals Resubmits New Drug Application for Potential Type 1 Diabetes Therapy

Share on Social Networks: